remestemcel-L has NOT been rejected by the F
DA. A CRL is in fact "approved if you meet condition X". Unlike Regenaron it has a flawless safety profile. Regenaron is on a phase 1/2/3 trial and needs to meet the endpoints for each phase. It looks good so far, but is for a different stage of the disease and largely unrelated to us. It is not a revolutionary new way to treat inflammatory disease and therfore is indeed not in same league as MSB's products.
trump taken to hospital, page-131
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.10 |
Change
-0.025(2.23%) |
Mkt cap ! $1.250B | |||
| Open | High | Low | Value | Volume |
| $1.13 | $1.16 | $1.04 | $14.57M | 13.49M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 21024 | $1.09 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.10 | 241 | 1 |
View Market Depth
| Last trade - 16.10pm 09/07/2024 (20 minute delay) ? |
| MSB (ASX) Chart |